Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Breast 1

Conditions

Breast Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Advanced Malignant Solid Tumors 3Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Blast Crisis 1Anemia 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × neratinib × Clear all
NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
73 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasms

NCT00397046 2018-09-14

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
21 enrolled 13 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡